Evaluation of blood TMB (bTMB) in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) with pemetrexed and platinum versus placebo plus chemo as first-line therapy for metastatic nonsquamous NSCLC.

被引：0
|
作者：
Chiara Garassino, Marina
Gadgeel, Shirish M.
Rodriguez-Abreu, Delvys
Felip, Enriqueta
Esteban, Emilio
Speranza, Giovanna
Hochmair, Maximilian
Francis Powell, Steven
Garon, Edward B.
Hui, Rina
Nogami, Naoyuki
Cristescu, Razvan
Morrissey, Michael
Loboda, Andrey
Kobie, Julie
Ayers, Mark
Piperdi, Bilal
Catherine Pietanza, Maria
Snyder, Alexandra
Reck, Martin
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[2] Karmanos Canc Inst, Detroit, MI USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
[4] Univ Las Palmas Gran Canaria, Complejo Hosp Univ Insular Maternoinfantil Gran C, Las Palmas Gran Canaria, Spain
[5] Hosp Univ Vall dHebron, Barcelona, Spain
[6] Hosp Univ Cent Asturias, Oviedo, Spain
[7] Univ Sherbrooke, Ctr Integre Cancerol Monteregie, Greenfield Pk, PQ, Canada
[8] Otto Wagner Hosp, Vienna, Austria
[9] Sanford Hlth, Sioux Falls, SD USA
[10] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[11] Westmead Hosp, Sydney, NSW, Australia
[12] Univ Sydney, Sydney, NSW, Australia
[13] Shikoku Canc Ctr, Matsuyama, Ehime, Japan
[14] Merck & Co Inc, Kenilworth, NJ USA
[15] German Ctr Lung Res, Airway Res Ctr North, LungenClin, Grosshansdorf, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9521
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC
    Mok, T. S. K.
    Wu, Y-L.
    Kudaba, I.
    Kowalski, D. M.
    Cho, B. C.
    Turna, H. Z.
    de Castro, G., Jr.
    Srimuninnimit, V.
    Laktionov, K. K.
    Bondarenko, I.
    Kubota, K.
    Caglevic, C.
    Karaszewska, B.
    Dang, T.
    Yin, L.
    Penrod, J.
    Lopes, G.
    ANNALS OF ONCOLOGY, 2019, 30 : 38 - 38
  • [42] Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC
    Chen, Pingyu
    Wang, Xintian
    Zhu, Shengwen
    Li, Hongchao
    Rui, Mingjun
    Wang, Yingcheng
    Sun, Haikui
    Ma, Aixia
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [43] Response to firstline (1L) pembrolizumab (pembro) plus chemotherapy (chemo) in nonsmall cell lung cancer (NSCLC) by blood tumor mutational burden (bTMB): the phase 2 KEYNOTE-782 trial
    Bar, Jair
    Esteban, Emilio
    Rodriguez-Abreu, Delvys
    Aix, Santiago Ponce
    Szalai, Zsuzsanna
    Felip, Enriqueta
    Gottfried, Maya
    Pulla, Mariano Provencio
    Robinson, Andrew
    Fulop, Andrea
    Rao, Suman B.
    Camidge, D. Ross
    Speranza, Giovanna
    Townson, Steven M.
    Kobie, Julie
    Ayers, Mark
    Dettman, Elisha J.
    McDaniel, Robert
    Jung, Byoungsok
    Burkhardt, David
    Mauntz, Ruth
    Csoszi, Tibor
    CANCER RESEARCH, 2023, 83 (08)
  • [44] KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%
    Reck, M.
    Rodr-Guez-Abreu, D.
    Robinson, A. G.
    Hui, R.
    Csoszi, T.
    Fulop, A.
    Gottfried, M.
    Peled, N.
    Tafreshi, A.
    Cuffe, S.
    O'Brien, M.
    Rao, S.
    Hotta, K.
    Leiby, M.
    Lubiniecki, G. M.
    Shentu, Y.
    Rangwala, R.
    Brahmer, J. R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [45] KEYNOTE-024: Pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) as first-line therapy for advanced NSCLC with a PD-L1 tumor proportion score (TPS) ≥50%
    Reck, M.
    Rodriguez-Abreu, D.
    Robinson, A.
    Hui, R.
    Csoszi, T.
    Fulop, A.
    Gottfried, M.
    Peled, N.
    Tafreshi, A.
    Cuffe, S.
    O'Brien, M. E.
    Rao, S.
    Hotta, K.
    Leiby, M.
    Lubiniecki, G.
    Shentu, Y.
    Rangwala, R.
    Brahmer, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [46] First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer: 5-year outcomes from the phase 3 KEYNOTE-590 study.
    Shah, Manish A.
    Sun, Jong-Mu
    Shen, Lin
    Kato, Ken
    Enzinger, Peter C.
    Adenis, Antoine
    Doi, Toshihiko
    Kojima, Takashi
    Li, Zhigang
    Kim, Sung-Bae
    Cho, Byoung Chul
    Mansoor, Wasat
    Li, Shau-Hsuan
    Sunpaweravong, Patrapim
    Maqueda, Maria Alsina
    Buchschacher, Gary L.
    Wu, Jimin
    Shah, Sukrut
    Bhagia, Pooja
    Metges, Jean-Philippe
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 250 - 250
  • [47] Randomized phase III study of first-line pembrolizumab plus pemetrexed/platinum followed by pembrolizumab and maintenance olaparib versus pemetrexed in patients with metastatic nonsquamous non-small cell lung cancer (NSCLC): KEYLYNK-006.
    Gray, Jhanelle Elaine
    Owonikoko, Taofeek Kunle
    Kato, Terufumi
    Zorrilla, Andres Felipe Cardona
    Wagman, Joanne
    Chen, Xinqun
    Zhao, Bin
    Schulz, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [48] First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): Analysis of KEYNOTE-590 and KEYNOTE-859 by tumor type.
    Shiu, Kai-Keen
    Rivera, Fernando
    Medley, Louise C.
    Aghmesheh, Morteza
    Dunne, Richard Francis
    Roy, Rajarshi
    Wyrwicz, Lucjan S.
    Larson, Timothy
    Metges, Jean-Philippe
    Mansoor, Wasat
    Goekkurt, Eray
    Moreira Antunes, Luiz Carlos
    Castro Oliden, Victor
    Jensen, Erin
    Shah, Sukrut
    Bordia, Sonal
    Bhagia, Pooja
    Lowery, Maeve Aine
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 345 - 345
  • [49] Phase 3 study of platinum-based chemotherapy with or without pembrolizumab for first-line metastatic, nonsquamous non-small cell lung carcinoma (NSCLC): KEYNOTE-189.
    Hall, Richard Delmar
    Gadgeel, Shirish M.
    Garon, Edward B.
    Bria, Emilio
    Reck, Martin
    Vida, John
    Zhou, Honghong
    Raftopoulos, Harry
    Gandhi, Leena
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
    Rha, S. Y.
    Wyrwicz, L. S.
    Weber, P. E. Y.
    Bai, Y.
    Ryu, M. H.
    Lee, J.
    Rivera, F.
    Alves, G. V.
    Garrido, M.
    Shiu, K. -k.
    Fernandez, M. Gonzalez
    Li, J.
    Lowery, M.
    Cil, T.
    Cruz, F. J. S. M.
    Qin, S.
    Yin, L.
    Bordia, S.
    Bhagia, P.
    Oh, D-y.
    ANNALS OF ONCOLOGY, 2023, 34 (03) : 319 - 320
12345